coin-img-ETHETH+0.68%coin-img-BTCBTC+0.73%coin-img-SOLSOL+0.65%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX-47.94%coin-img-XRPXRP+0.17%coin-img-HYPEHYPE-2.93%coin-img-TRXTRX+0.61%coin-img-ETHETH+0.68%coin-img-BTCBTC+0.73%coin-img-SOLSOL+0.65%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX-47.94%coin-img-XRPXRP+0.17%coin-img-HYPEHYPE-2.93%coin-img-TRXTRX+0.61%coin-img-ETHETH+0.68%coin-img-BTCBTC+0.73%coin-img-SOLSOL+0.65%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX-47.94%coin-img-XRPXRP+0.17%coin-img-HYPEHYPE-2.93%coin-img-TRXTRX+0.61%coin-img-ETHETH+0.68%coin-img-BTCBTC+0.73%coin-img-SOLSOL+0.65%coin-img-USDCUSDC+0.02%coin-img-UBOXUBOX-47.94%coin-img-XRPXRP+0.17%coin-img-HYPEHYPE-2.93%coin-img-TRXTRX+0.61%

Mankind Pharma Q1 FY27 Net Profit Falls 21% to ₹558.49 Crore

AI Market Summary
Mankind Pharma reported a weaker Q1 FY27, with consolidated net profit down 20.69% YoY to ₹558.49 crore alongside a revenue decline and higher total expenses, pushing basic EPS to ₹13.53 from ₹17.06. The results constitute a negative earnings catalyst for the company's listed equity and can weigh on near-term risk appetite toward Indian healthcare names, though broader market impact should be contained.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT+1.24%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Mankind Pharma reported its Q1 FY27 results, posting a consolidated net profit of ₹558.49 crore, down 20.69% year on year. Revenue came in at ₹2,964.05 crore, also lower from a year earlier. Total expenses rose to ₹2,241.44 crore. Basic earnings per share slipped to ₹13.53 from ₹17.06. The update marks the latest quarterly financial disclosure for the company's listed security ONUS and is viewed as a key earnings catalyst for equity investors.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.